- Moderna and Merck announce mRNA cancer vaccine Intismeran reduces melanoma spread
- Trump aims to revive Keystone XL pipeline expansion in trade talks with Canada
- Progressive candidates’ primary victories shape Democratic midterm strategy
- Israeli military confirms shooting at vehicle containing five-year-old girl
- Palestinian Authority faces ongoing financial crisis amid growing challenges
- North Korea Rejects Trump-Kim Talks, Affirms US as ‘Hostile’ Presence
- European Socialists face rift as Denmark’s Frederiksen opposes Spain
- Zelensky dismisses defence minister amid calls for elections in Ukraine
UK public borrowing exceeds official forecast in September
FT.com Tweet
Government borrowing overshot official projections in September, which is a sign of the difficult fiscal position that the Chancellor faces as she puts the finishing touches on her first tax and spending budget.
CITY AM Tweet
Get you up to speed: Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread
Moderna and Merck have reported promising interim results from a late-stage trial of their personalised mRNA cancer vaccine, Intismeran, which reduced melanoma recurrence and spread. The companies are currently in discussions with regulators regarding the treatment.
Moderna and Merck are in discussions with regulators regarding the approval of the Intismeran vaccine, aimed at high-risk melanoma patients. Detailed study results are anticipated to be presented at an upcoming medical meeting, following the initial positive interim findings released on Wednesday.
Following the announcement of promising trial results for the mRNA cancer vaccine Intismeran, Merck confirmed that it is in discussions with regulators regarding the treatment’s approval. Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, remarked that the findings could “signal a new era for treating solid-tumour cancers,” highlighting the significance of this development in immunotherapy.
What remains unclear — Detailed results of the late-stage trial are yet to be released.
Moderna and Merck announce mRNA cancer vaccine Intismeran reduces melanoma spread
News|HealthModerna, Merck unveil mRNA-based cancer vaccine that cuts spread
Moderna’s mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.
Published On 19 Aug 202619 Aug 2026
Moderna and Merck have announced that a personalised mRNA cancer vaccine called Intismeran reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent Moderna’s shares surging as much as 160 percent.
Interim results of the study released on Wednesday found that the treatment met both goals of reducing cancer recurrence and preventing the spread of tumours. Detailed results of the study have not been released but are expected to be shared at an upcoming medical meeting, according to the drugmaker.
Moderna President Stephen Hoge said thousands of patients who have had high-risk melanoma tumours removed in surgery could benefit by next year if the vaccine is approved by regulators. According to the National Cancer Institute, there were more than 1.5 million people in the US living with melanoma in 2023.
Developed alongside pharmaceutical giant Merck, Moderna tested the vaccine with immunotherapy drug Keytruda.
A nurse loads a syringe with a vaccine at an inoculation station [File: Rogelio V Solis/AP Photo]
The experimental vaccine trains the patient’s immune system to fight tumours by targeting mutations in cancer cells. Similar approaches are being tested to combat other cancers such as lung, breast and pancreatic cancers.
Previous studies have suggested that mRNA vaccines could help immune systems recognise and attack cancer cells in mice and in analyses of medical records of cancer patients. Findings from the studies came at a time when the administration of United States President Donald Trump cut funding for mRNA research.
The development is the first positive late-stage trial result for an mRNA cancer vaccine. Merck said the companies are already in talks with regulators about the treatment.
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, said the Moderna results could signal a new era for treating solid-tumour cancers.
“The positive hit here leads us into truly this next phase in immunotherapy,” Knudsen said. “This is an auspicious start – this is where things begin.”
Get you up to speed: What is Keystone XL—and why does Trump want to bring it back to life?
U.S. President Donald Trump announced plans to revive the Keystone XL pipeline expansion project in connection with a pending trade deal with Canada. The confirmation came amid ongoing discussions regarding trade relations between the two nations.
U.S. President Donald Trump has initiated discussions regarding the revival of the Keystone XL pipeline expansion project in the context of ongoing trade negotiations with Canada. No specific timeline for the revival or operational details have been released as the talks progress.
U.S. President Donald Trump announced intentions to revive the Keystone XL pipeline expansion project, linking it to a forthcoming trade agreement with Canada. This announcement has prompted discussions among stakeholders regarding potential impacts on energy markets and environmental regulations.
What remains unclear — Details regarding the timeline and specific terms of the proposed revival of the Keystone XL pipeline have not been disclosed.
Trump aims to revive Keystone XL pipeline expansion in trade talks with Canada

U.S. President Donald Trump says he is looking to revive the the Keystone XL pipeline expansion project as part of a pending trade deal with Canada.
What to Watch
Amazon prime - TV & Netflix
What to Watch
Love Sports
- Readers Digest
Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.



